NEW YORK (GenomeWeb News) – ACE BioSciences has tapped CLC Bio to develop a customized bioinformatics platform that will support its work in vaccine target discovery and validation, CLC Bio said today.
 
Under the terms of the agreement, CLC Bio will upgrade ACE BioSciences' current bioinformatics platform to ensure that the firm can compare, rank, and prioritize potential vaccine targets.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.